Skip to main content
NRXP
NASDAQ Life Sciences

FDA 确认 NRX-100 的清晰、加速 NDA 路径将于 2026 年 6 月完成，无需新试验

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$1.96
Mkt Cap
$59.283M
52W Low
$1.58
52W High
$3.84
Market data snapshot near publication time

summarizeSummary

NRX Pharmaceuticals 宣布了一项重大监管突破，确认了其药物候选物 NRX-100 (Ketamine) 的清晰、加速 New Drug Application (NDA) 路径将于 2026 年 6 月完成。在 Type C FDA 会议之后，公司收到了确认，无需额外的临床试验、非临床数据或桥接研究来提交申请。这一发展，加上对 NRX-100 的更广泛的拟议适应症，显著降低了监管过程的风险，并减少了未来的开发成本和时间表。对于一家小型生物技术公司来说，这代表着一个重大的积极催化剂，因为它使得一个关键资产更接近潜在的商业化。投资者现在将关注成功提交 NDA 的截止日期，即 2026 年 6 月。

在该公告发布时，NRXP的交易价格为$1.96，交易所为NASDAQ，所属行业为Life Sciences，市值约为$5928.3万。 52周交易区间为$1.58至$3.84。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed NRXP - Latest Insights

NRXP
Apr 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Sentiment: Positive
View Wiseek Article
NRXP
Apr 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Presidential Order to Fast-Track Psychedelic Drug Approvals Directly Benefits NRx Pharmaceuticals
Sentiment: Positive
View Wiseek Article
NRXP
Apr 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
Sentiment: Positive
View Wiseek Article
NRXP
Mar 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Hope Therapeutics, NRXP Subsidiary, Partners with Emobot to Deploy AI-Powered Depression Monitoring
Sentiment: Positive
View Wiseek Article
NRXP
Mar 24, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Stockholders Approve Significant Increase in Annual Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
8
NRX Pharmaceuticals Reports Going Concern, Massive Dilution, and Key Regulatory Progress in Annual 10-K
Sentiment: Negative
View Wiseek Article
NRXP
Mar 16, 2026, 7:36 AM EDT
Source: Reuters
Importance Score:
9
FDA Confirms Clear, Accelerated NDA Path for NRX-100 by June 2026, No New Trials Required
Sentiment: Positive
View Wiseek Article
NRXP
Feb 23, 2026, 5:00 PM EST
Filing Type: DEF 14A
Importance Score:
8
NRX Pharmaceuticals Seeks Shareholder Approval for Substantial Increase in Equity Incentive Plan Share Reserve
Sentiment: Negative
View Wiseek Article
NRXP
Feb 17, 2026, 9:21 AM EST
Filing Type: 8-K
Importance Score:
9
NRX Pharmaceuticals Secures Clear FDA Path for Full NDA Approval of NRX-100 with Broader Indication
Sentiment: Positive
View Wiseek Article
NRXP
Feb 17, 2026, 9:20 AM EST
Filing Type: 424B5
Importance Score:
9
NRX Pharmaceuticals Announces Highly Dilutive $20M At-The-Market Equity Offering
Sentiment: Negative
View Wiseek Article